{"meshTags":["Antineoplastic Agents","Isocitrate Dehydrogenase","Leukemia, Myeloid, Acute","Mutation","Enzyme Inhibitors","Humans","Clinical Trials, Phase I as Topic"],"meshMinor":["Antineoplastic Agents","Isocitrate Dehydrogenase","Leukemia, Myeloid, Acute","Mutation","Enzyme Inhibitors","Humans","Clinical Trials, Phase I as Topic"],"genes":["IDH1","inhibits mutant IDH1"],"publicationTypes":["News"],"abstract":"The experimental drug AG-120, which inhibits mutant IDH1, showed promising results in a phase I trial in patients with relapsed or refractory acute myeloid leukemia. ","title":"IDH1 inhibitor shows promising early results.","pubmedId":"25583779"}